Investors’ focus in the coming week will be honed on tariff announcements. April 2 is the day when numerous tariffs recently ...

That’s why vendors that consistently negotiate effectively take a different approach: They communicate the cost price increase with clear SKU-level price lists and timelines. Not only with Amazon but ...

Japan's core inflation hit 3.0% in February and an index stripping away the effect of fuel rose at the fastest pace in nearly ...

The data shown on this page correspond to the data described on the International Monetary Fund's Dissemination Standards Bulletin Board (DSBB). For a fuller explanation of the DSBB and the ...

Let go of the tethers and embrace the freedom of living life cable-free. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Wireless gaming ...

There are a lot of different numbers cited for the average annual return of the index. And while the average return is easy to compute, it’s important to define what you’re computing.

Because of this lack of appreciation, I am seriously considering not giving the scholarships this year. It’s disappointing to put money toward something meaningful and feel as though it’s ...

The Third Annual World Bank Conference on Transport Economics was held on March 14, 2025, in Washington, D.C., on the sidelines of Transforming Transportation. The conference was organized by the ...

The Annual and Half-year Reports are also available in our app - with the advantage that they can also be read offline and can be navigated in a particularly user-friendly manner. Since 1998 the ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet medical journal. Lenacapavir stops ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet, external medical journal.